Adaptive Treatment for Early Smoking Cessation Relapse
This study is looking for smokers who want to quit and have found it difficult to stop using medications. It aims to improve how treatment decisions are made for these individuals. You'll receive free products for 12 weeks, which could include nicotine replacement therapies (patches and lozenges), varenicline (a medication to help you quit smoking), or e-cigarettes (a harm reduction product). The specific treatment you receive will depend on how you respond to earlier treatments. The study will measure if you are still smoking after your initial medication course at 8 weeks. This study is currently unclear about its recruitment status, but plans to enroll 544 participants.
- Study design
- This interventional study plans to enroll 544 participants. It will test different approaches to help people quit smoking.
- What's involved
- All visits and assessments will be remote. You will complete 8 surveys over six months.
- Compensation
- All treatments will be provided free of charge for the first 12 weeks.
- Follow-up
- The study team will contact participants 6 months after the first study phone call to complete another survey.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Non-responders after initial course of FDA-approved medication8 weeks
7-day point prevalence abstinence at Week 8 among non-responders at Week 4